Name: MarketsandMarkets Next Gen Microbiome and Probiotics Virtual Conference - ( Time Zone - Eastern Time Zone (EST)
Start: 2020-06-22
End: 2020-06-23

CONFERENCE AGENDA

Online Registration	10:30 - 10:50
Welcome note from MarketsandMarkets	10:50 - 10:55
Opening Remarks from the Chairman George Pell, CEO and Founder, Thirty-Six	10:55 - 11:00
Keynote Presentation: Systems biology platform for nutritional and precision medicine approaches to chronic diseases Momo Vuyisich, Chief Scientific Officer , Viome	11:00 - 11:25
MICROBIOME AND PROBIOTICS DISCOVERY R&D
Multi-Microbiome Effects: Probiotic Strategies To Target Next Generation Microbes Noelle Patno, Digestive Health Therapeutic Platform Lead, , Metagenics, USA	11:25 - 11:50
Flexible automation solutions for the microbiology workflow Shai Kaplan, CEO, Co-Founder, SciRobotics, USA	11:50 - 12:20
bit-MAP, a new single-cell whole-genome analysis platform for microbes Sunao Fujioka, CEO, bitBiome, Japan	12:20 - 12:35
Microbiome Analysis Platform for Clinical Research, Discovery and Insights Jacob Bak Holm, Director, Scientific Operations, , Clinical Microbiomics, Denmark	12:35 - 12:50
First Medical Probiotic for Type 2 Diabetes that Targets the Gut Microbiome to Provide Glucose Control Jason Cadle, National Sales Manager, Microbiology International, USA	12:50 - 13:20
CLINICAL APPLICATIONS OF MICROBIOME IN HEALTH AND DISEASE
Regulation of appetite by a single strain: from in-vitro mechanism to clinical results Gregory Lambert, CEO, VP, R&D, TargEDys, France	13:20 - 13:45
The Microbiome \| reshaping lives, and saving some too George Pell, CEO and Founder, Thirty-Six	13:45 - 14:10
The importance of the microbiome and a technology to assess and improve it Erika Ebbel Angle , CEO, Co-Founder , Ixcela, USA	14:10 - 14:40
Electrostatic Spray Drying, a Gentle Approach to Drying Thermosensitive Microorganisms Bogdan Zisu, Senior Process Engineer, Fluid Air, Australia	14:40 - 15:10
Closing Remarks from the Chairman	15:10 - 15:15

Online Registration	10:30 - 10:50
Welcome note from MarketsandMarkets	10:50 - 10:55
Opening Remarks from the Chairman George Pell, CEO and Founder, Thirty-Six	10:55 - 11:00
Keynote Presentation: Precise Microbiome Editing: A Foundation for Evidence-Based Microbiome Products in the Consumer Health Space Yug Varma, CEO, Phi Therapeutics	11:00 - 11:25
EMERGING TECHNIQUES USED TO STUDY MICROBIOME AND FUTURE OF PROBIOTICS
The spectacular role of the human microbiome in preventing post-prandial or metabolic endotoxemia, the number one cause of mortality worldwide. Kiran Krishnan, Co-Founder, Chief Scientific Officer, Microbiome Labs, USA	11:25 - 11:50
Lysates vs Live – differences and benefits Maya Ivanjesku, Chief Scientific Officer, M2B Pharma	11:50 - 12:15
Gut microbiota-mediated colonisation resistance and intestinal pathogens Julie McDonald, Lecturer, Imperial College London	12:15 - 12:40
Pharma or Consumer - A New Strategy for Preclinical Discovery and Product Development Larry Weiss, CEO, Symbiome, USA	12:40 - 13:10
Mining the Microbiome for Novel Therapeutics Kareem Barghouti, CEO, Pragma Bio	13:10 - 13:35
BUSINESS COMMERCIALIZATION AND R&D COLLABORATIONS
Interactive and Reproducible Metagenomics Data Analysis with MEGAN6 UE and MORPHEUS Oliver Deusch, Scientific Product Manager, Computomics	13:35 - 14:05
The challenges of leveraging microbiome data in line with your company’s goals Nils Hijlkema, CCO , TenWise	14:05 - 14:20
Closing remarks from the Chairman	14:20 - 14:25